Diagnostic value of S100P for pancreatic cancer: a meta-analysis

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9479-9485

  Hu, Haolin ^a   Zhang, Qi ^a   Huang, Chenfei ^b   Shen, Yi ^b   Chen, Xundi ^b   Shi, Xin ^a   Tang, Wenhao ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Meta analysis; PC; S100P

Indexed keywords

CALCIUM BINDING PROTEIN; S100P PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

AREA UNDER THE CURVE; HUMAN; META ANALYSIS; PANCREATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AREA UNDER CURVE; CALCIUM-BINDING PROTEINS; HUMANS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84922392882     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2461-4     Document Type: Review

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63(1):11–30.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.
4. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1766–73.
5. Grantzdorffer I, Carl-McGrath S, Ebert MP, et al. Proteomics of pancreatic cancer. Pancreas. 2008;36(4):329–36.
6. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–5.
7. Bunger S, Laubert T, Roblick UJ, et al. Serum biomarkers for improved diagnostic of PC: a current overview. J Cancer Res Clin Oncol. 2011;137(3):375–89.
8. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12(2):442–6.
9. Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European group on tumor markers (EGTM) status report. Ann Oncol. 2010;21(3):441–7.
10. Parkkila S, Pan PW, Ward A, et al. The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol. 2008;8:2.
11. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63(10):2649–57.
12. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
13. Devillé WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9.
14. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
15. Liu H, Shi J, Anandan V, et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 2012;136(6):601–9.
16. Bournet B, Pointreau A, Souque A, et al. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration Samples. Pancreatology. 2012;12(1):27–34.
17. Dim DC, Jiang F, Qiu Q, et al. The usefulness of S100p, mesothelin, fascin, prostate stem cell antigen and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn Cytopathol. 2014;42(3):193–9.
18. Kosarac O, Takei H, Zhai QJ. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology. Acta Cytol. 2011;55(2):142–8.
19. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma with implication of their roles in early tumorigensis. Am J Surg Pathol. 2008;2(1):78–91.
20. Chen Y, Zheng B, Robbins DH, et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multi marker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer. 2007;120(7):1511–7.
21. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166(1):81–92.
22. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol. 2003;201:63–74.
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
24. Matsuno S, Egawa S, Fukuyama S, et al. PC registry in Japan: 20 years of experience. Pancreas. 2004;28(3):219–30.
25. 2+-binding properties. Eur J Biochem. 1992;207(2):541–7.
26. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33(7):637–68.
27. Ohuchida K, Mizumoto K, Egami T. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Can Res. 2006;12(18):5411–6.
28. Deng H, Shi J, Wilkerson M, et al. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008;129(1):81–8.
29. Yasuhisa M, Takao O, Hiroshi K, et al. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Pancreas. 2013;42(2):187–92.
30. Glas AS, Lijmer JG, Prins MH. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129–35.